natgillin/translations-raw huggingface dataset:
Manufacturer responsible for batch release: To be completed nationally
Izdelovalec, odgovoren za sproščanje serij:
For the treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
zdravilo je namenjeno zdravljenju in preprečevanju nekrotičnega enteritisa pri brojlerjih, ki jih povzroča Clostridium perfringens.
Pack sizes:
Brojlerji:
For the treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae.
Prašiči: zdravljenje in metafilaksa enzootske pneumonije, ki jo povzroča Mycoplasma Hyopneumoniae.
Peak serum levels were observed at 4 hours after dosing.
Največjo vsebnost v serumu doseže v 4 urah.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Bottles containing 150 g or 1.5 kg
Velikosti pakuranja: Plastenka s 150 g Plastenka z 1,5 kg.
Route of administration
B. NAVODILO ZA UPORABO
In pigs, lincomycin is rapidly absorbed following oral administration.
Linkomicin se po peroralnem dajanju pri prašičih hitro resorbira.
Chickens
Brojlerji
Dosage:
Serija:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
NAVEDBA UČINKOVINE IN DRUGIH SESTAVIN
Implementation of the position by the Member States:
Uveljavitev stališča v državah članicah:
Adoption of CMDh position by consensus:
Soglasno sprejetje stališča skupine CMDh:
26 July 2019
26. julij 2019
26 June 2019
26. junij 2019
May 2019 CMDh meeting
Zasedanje skupine CMDh maja 2019
Section 4.4
Poglavje 4.4
Rare (affects less than 1 in 1,000 people)
Redki (pojavijo se pri manj kot 1 bolniku izmed 1 000)
Adopted at the 14-17 March 2016 PRAC
Sprejeto na seji odbora PRAC med 14. in 17. marcem 2016
Other side effects include:
Drugi neželeni učinki so:
The increased risk appears to be related to the degree and duration of immunosuppression.
Kaže, da je povečano tveganje povezano s stopnjo in trajanjem imunosupresivnega zdravljenja.
Therefore, when taking <X>, avoid excessive exposure to sunlight, wear protective clothing and use protective sunscreen with a high protection factor.
Zato se med jemanjem zdravila <X> čim bolj izogibajte izpostavljenosti sončnim žarkom, nosite zaščitna oblačila in uporabljajte zaščitna sredstva za sončenje z visokim zaščitnim faktorjem.
• Low fibrinogen levels in the blood (a protein involved in blood clotting)
• Nizke ravni fibrinogena v krvi (beljakovine, vključene v strjevanje krvi)
Not known side effects are (frequency cannot be estimated from the available data):
Neželeni učinki z neznano pogostnostjo so (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti):
4.8 Undesirable effects
Poglavje 4.8 Neželeni učinki
• various types of cancers including blood, lymph and skin cancers
• različne vrste raka, vključno s krvnim, limfnim in kožnim rakom
Taking <X> could put you at greater risk of:
Zaradi jemanja zdravila <X> se poveča tveganje za:
• developing a serious condition called Macrophage Activation Syndrome (excessive activation of white blood cells associated with inflammation), which usually occurs in people who have certain types of arthritis
• pojav resnega stanja, imenovanega sindrom aktivacije makrofagov (čezmerna aktivacija belih krvničk, povezana z vnetjem), kar se običajno pojavi pri osebah, ki imajo določene vrste artritisa
It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.
Poročali so, da prekinitev imunosupresivnega zdravljenja lahko povzroči delno regresijo limfoproliferativne bolezni.
• lymphoproliferative disorders o treatment with <X> increases your risk of getting a type of cancer called lymphoproliferative disorder.
• limfoproliferativne bolezni o zdravljenje z zdravilom <X> poveča tveganje za raka, imenovanega limfoproliferativna bolezen.
Neoplasms benign and malignant (including cysts and polyps)
Benigne in maligne novotvorbe (vključno s cistami in polipi)
Axitinib should be discontinued if the patient develops nephrotic syndrome.
Zdravljenje z aksitinibom je treba ukiniti, če se pri bolniku pojavi nefrotski sindrom.
For patients who develop moderate to severe proteinuria, reduce the dose or temporarily interrupt axitinib treatment (see section 4.2).
Pri bolnikih, pri katerih se pojavi zmerna do huda proteinurija, je treba odmerek zmanjšati ali začasno prekiniti zdravljenje z aksitinibom (glejte poglavje 4.2).
What you need to know before you <take> <use> X Warnings and precautions Talk to your doctor <or> <pharmacist> <or nurse> before <taking> <using> X If you are receiving immunosuppressive therapy, taking <X> could put you at greater risk of:
Kaj morate vedeti, preden <boste vzeli> <boste uporabili> zdravilo X Opozorila in previdnostni ukrepi Pred začetkom <jemanja> <uporabe> zdravila X se posvetujte <z> zdravnikom <ali> <farmacevtom> <ali medicinsko sestro>.
In clinical studies with axitinib, proteinuria, including that of Grade 3 and 4 severity, was reported (see section 4.8).
V kliničnih študijah z aksitinibom so poročali o proteinuriji, vključno s proteinurijo s 3. in 4. stopnjo izraženosti (glejte poglavje 4.8).
• tumours, including skin cancer.
• pojav tumorjev, tudi za pojav kožnega raka.
Package Leaflet (PL) No changes to the PL are needed.
Navodilo za uporabo: Spremembe navodila za uporabo niso potrebne.
With treatment regimen containing multiple immunosuppressants (including thiopurines), this may lead to death.
Pri shemi zdravljenja z več imunosupresivnimi zdravili (vključno s tiopurini) to lahko povzroči smrt.
Mercaptopurine (XALUPRINE); azathioprineLymphoproliferative disorders (EPITT no 18503)
Merkaptopurin (XALUPRINE); azatioprinlimfoproliferativne bolezni (št. EPITT 18503)
Tigecycline (TYGACIL) - Hypofibrinogenaemia (EPITT no
Tigeciklin (TYGACIL) - hipofibrinogenemija (št. EPITT
Physicians should be attentive to symptoms of infection such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.
Zdravniki morajo biti pozorni na simptome okužb, kot sta okužba z EBV in citomegalovirusom (CMV), saj sta znana sprožilca sindroma aktivacije makrofagov.
Mutagenicity and carcinogenicity/Carcinogenicity
Mutagenost in kancerogenost/kancerogenost.
Rare: neoplasms including lymphoproliferative disorders, skin cancers (melanomas and nonmelanomas), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ…(see section
Redki: novotvorbe, vključno z limfoproliferativnimi boleznimi, kožnim rakom (melanomskim in nemelanomskim), sarkomom (Kaposijevim in ne-Kaposijevim) in rakom materničnega vratu in situ (glejte poglavje 4.4).
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities.
Zato je treba shemo zdravljenja z več imunosupresivnimi zdravili (vključno s tiopurini) uporabljati previdno, saj lahko privede do limfoproliferativnih bolezni, pri čemer so poročali tudi o smrtnih izidih.
Patients receiving immunosuppressive therapy, including <azathioprine> <mercaptopurine> are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ.
Bolniki, ki prejemajo imunosupresivno terapijo, vključno z <azatioprinom> <merkaptopurinom>, so izpostavljeni povečanemu tveganju za pojav limfoproliferativnih bolezni in drugih malignih bolezni, predvsem kožnega raka (melanomskega in nemelanomskega), sarkoma (Kaposijevega in neKaposijevega) ter raka materničnega vratu in situ.
Package leaflet (mercaptopurine and azathioprine) 2.
Navodilo za uporabo (merkaptopurin in azatioprin) 2.
A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.
Kombinacija več imunosupresivnih zdravil, ki se dajejo sočasno, poveča tveganje za limfoproliferativne bolezni, povezane z virusom Epstein-Barr (EBV).
Frequency not known (cannot be estimated from the available data): hypofibrinogenaemia
Bolezni krvi in limfatičnega sistema Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov): hipofibrinogenemija
If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with mercaptopurine should be discontinued.
Če se pojavi sindrom aktivacije makrofagov, je treba čim prej začeti z oceno in zdravljenjem, zdravljenje z merkaptopurinom pa je treba prekiniti.
Summary of Product Characteristics (mercaptopurine)
Povzetek glavnih značilnosti zdravila (merkaptopurin)
o A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV)-associated lymphoproliferative disorders).
o Kombinacija več imunosupresivnih zdravil, ki se dajejo sočasno, poveča tveganje za bolezni limfnega sistema zaradi virusne okužbe (limfoproliferativne bolezni, povezane z virusom Epstein-Barr (EBV)).
If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with azathioprine should be discontinued.
Če se pojavi sindrom aktivacije makrofagov, je treba čim prej začeti z oceno in zdravljenjem, zdravljenje z azatioprinom pa je treba prekiniti.
Monitoring for proteinuria before initiation of, and periodically throughout, treatment with axitinib is recommended.
Pred začetkom zdravljenja z aksitinibom in v rednih časovnih presledkih med njim je priporočljivo spremljanje glede pojava proteinurije.
Summary of Product Characteristics (mercaptopurine and azathioprine): Section 4.8 Undesirable effects
Povzetek glavnih značilnosti zdravila 4.8 Neželeni učinki
Summary of Product Characteristics (azathioprine)
Povzetek glavnih značilnosti zdravila (azatioprin)
Axitinib (INLYTA) - Nephrotic syndrome (EPITT no
Aksitinib (INLYTA) - nefrotski sindrom (št. EPITT 18484)
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD) (unlicensed indication), and there could potentially be an increased susceptibility for developing the condition with the use of mercaptopurine.
Sindrom aktivacije makrofagov je znana, življenjsko nevarna motnja, ki se lahko pojavi pri bolnikih z avtoimunskimi boleznimi, zlasti pri bolnikih z vnetno črevesno boleznijo (neodobrena indikacija).
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of azathioprine.
Sindrom aktivacije makrofagov je znana, življenjsko nevarna motnja, ki se lahko pojavi pri bolnikih z avtoimunskimi boleznimi, zlasti pri bolnikih z vnetno črevesno boleznijo.
10 mg + 20 mg + 30 mg blister (PVC/alu) in a card
10 mg + 20 mg + 30 mg filmsko obložena tableta peroralna uporaba pretisni omot (PVC/alu) v zgibanki
These include, among others:
Mednje med drugim sodijo:
Approximately 90% of patients included in this analysis were Asian or White.
Približno 90 % bolnikov, ki so bili vključeno v to analizo, je bilo Azijcev ali belcev.
Therefore, the statistical significance of OS improvement could not be formally assessed.
Zato statistične pomembnosti izboljšanja OS ni bilo mogoče formalno oceniti.
• Swallow the tablet whole with a glass of water.
• Tableto pogoltnite celo, s kozarcem vode.
• if you ever had any other lung problems.
• če ste kadarkoli imeli druge težave s pljuči.
• Take the tablet at about the same time each day.
• Tableto vzemite vsak dan ob približno istem času.
Dose (once daily)
Odmerek (enkrat na dan)
* Fatal events were reported.
* Poročali so o dogodkih s smrtnim izidom.
Data based on data cut-off date of 29 July 2016.
Podatki temeljijo na podatkih, zbranih do datuma zaključka zbiranja podatkov: 29. julij 2016.
Patients should be encouraged to take their dose at approximately the same time each day.
Bolnike je treba spodbujati, da vzamejo odmerek vsak dan ob približno istem času.
Age, race, gender, body weight
Starost, rasa, spol, telesna masa
This medicine may pose a risk for the environment.
To zdravilo je lahko okolju nevarno.
Assessment of EGFR mutation status
Določanje statusa mutacij EGFR
When assessing the EGFR mutation status of a patient, it is important that a well-validated and robust methodology is chosen to avoid false negative or false positive determinations.
Pri določanju statusa mutacij EGFR pri bolniku je pomembno, da izberete dobro validirano in robustno metodologijo, da se izognete lažno negativnim ali lažno pozitivnim rezultatom.
Vizimpro has not been studied in children or adolescents and it must not be given to patients under the age of 18 years.
Zdravila Vizimpro niso preučevali pri otrocih ali mladostnikih in ga ne smemo dajati bolnikom, mlajšim od 18 let.
This medicine contains lactose (found in milk or dairy products).
To zdravilo vsebuje laktozo (ki je prisotna v mleku ali mlečnih izdelkih).
Food does not alter bioavailability to a clinically meaningful extent.
Hrana ne spremeni biološke uporabnosti v klinično pomembnem obsegu.
However, according to the hierarchical testing approach, the analysis was stopped with the testing of ORR as the statistical significance was not reached.
Vendar pa so analizo skladno s pristopom hierarhičnega testiranja ustavili pri testiranju ORR, saj niso dosegli statistične pomembnosti.
Symptoms may be similar to those from lung cancer.
Simptomi so lahko podobni tistim, ki spremljajo pljučnega raka.
Do not stop taking Vizimpro unless your doctor tells you to.
Zdravila Vizimpro ne prenehajte jemati, razen če vam to naroči zdravnik.
EGFR mutation status was determined by a standardised and commercially available test kit.
Status mutacij EGFR so določili s standardiziranim in komercialno dostopnim testnim kompletom.
The tablets should be swallowed with water and can be taken with or without meals.
Tablete je treba pogoltniti z vodo in se jih lahko jemlje s hrano ali brez nje.
c. Based on the stratified Cochran-Mantel-Haenszel test.
c. Na podlagi stratificiranega Cochran-Mantel-Haenszelovega testa.
Dose modifications may be required based on individual safety and tolerability.
Odmerek bo morda treba prilagoditi glede na posameznikovo varnost in prenašanje.
Race was 23% White, 77% Asian, and < 1% Black.
Kar zadeva raso, je bilo 23 % belcev, 77 % Azijcev in < 1 % temnopoltih.
• You can take the tablet with or without meals.
• Tableto lahko vzamete s hrano ali brez nje.
The other ingredients are:
- Druge sestavine zdravila so:
Advise patients to use protective clothing and sunscreen before exposure to the sun.
Bolnikom svetujte, naj pred izpostavitvijo soncu uporabijo zaščitna oblačila in kremo za zaščito pred soncem.
If there is any possibility that you may become pregnant you must use effective contraception during treatment, and for at least 17 days afterwards.
Če obstaja kakršnakoli možnost, da zanosite, morate med zdravljenjem in še najmanj 17 dni po njem uporabljati učinkovito kontracepcijo.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Znotraj vsake skupine pogostnosti so neželeni učinki predstavljeni po padajoči resnosti.
In particular, the effects of some medicines may increase when taken with Vizimpro.
Predvsem se učinki nekaterih zdravil lahko povečajo, kadar jih jemljete skupaj z zdravilom Vizimpro.
a. From stratified Cox Regression.
a. Iz stratificirane Coxove regresijske analize.
All effects occurred at systemic exposure below that in humans at the recommended dose of 45 mg once daily.
Vsi učinki so se pojavili pri sistemski izpostavljenosti, ki je bila manjša od tiste pri človeku pri priporočenem odmerku 45 mg enkrat na dan.
• If you are being treated with any of the medicines listed in section Other medicines and Vizimpro.
• če se zdravite s katerimkoli izmed zdravil, ki so navedena v poglavju Druga zdravila in zdravilo Vizimpro.
The safety and efficacy of Vizimpro in the paediatric population (< 18 years of age) have not been established.
Pediatrična populacija Varnost in učinkovitost zdravila Vizimpro pri pediatrični populaciji (starost < 18 let) nista bili dokazani.
Contact your doctor immediately if you notice any of the following side effects - you may need urgent medical treament:
Takoj obvestite zdravnika, če opazite kateregakoli izmed naslednjih neželenih učinkov - morda boste potrebovali nujno zdravniško pomoč:
The median duration of treatment with Vizimpro across the pooled data set was 66.7 weeks.
Mediano trajanje zdravljenja z zdravilom Vizimpro v združeni zbirki podatkov je bilo 66,7 tedna.
Diarrhoea may result in dehydration with or without renal impairment, which could be fatal if not adequately treated.
Diareja lahko povzroči dehidracijo z ledvično okvaro ali brez nje, ki je lahko smrtna, če je ne zdravimo ustrezno.
Anti-diarrhoeal medicinal products (e.g., loperamide) should be used and, if necessary, escalated to the highest recommended approved dose.
Treba je uporabiti antidiaroike (npr. loperamid) in po potrebi odmerek povečevati do največjega priporočenega odobrenega odmerka.
b. Based on the stratified log-rank test.
b. Na podlagi stratificiranega log-rank testa.
The following medicines may reduce how well Vizimpro works:
Naslednja zdravila lahko zmanjšajo učinkovitost zdravila Vizimpro:
A phototoxicity study with dacomitinib in pigmented rats showed no phototoxicity potential.
Študija fototoksičnosti z dakomitinibom pri pigmentiranih podganah ni pokazala potenciala za fototoksičnost.
The European Medicines Agency has waived the obligation to submit the results of studies with dacomitinib in all subsets of the paediatric population in NSCLC indication (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z dakomitinibom za vse podskupine pediatrične populacije pri indikaciji NSCLC (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
However, based on the oral bioavailability of 80%, these membrane transport proteins are unlikely to have any impact on dacomitinib absorption.
Na podlagi peroralne biološke uporabnosti, ki znaša 80 %, ni verjetno, da bi te membranske prenašalne beljakovine imele vpliv na absorpcijo dakomitiniba.
If the patient vomits or misses a dose, an additional dose should not be taken and the next prescribed dose should be taken at the usual time the next day.
Če bolnik bruha ali izpusti odmerek, ta dan ne sme vzeti dodatnega odmerka, naslednji predpisani odmerek pa mora vzeti naslednji dan ob običajnem času.
The demographic characteristics of the overall study population were 60% female; median age at enrolment was 62 years with 10.8% being ≥ 75 years old.
Demografske značilnosti celokupne študijske populacije so bile naslednje: 60 % žensk, mediana starost ob vključitvi pa je bila 62 let, pri čemer je bilo 10,8 % bolnikov starih ≥ 75 let.
Subgroup analyses of PFS per IRC review based on baseline characteristics were consistent with those from the primary analysis of PFS.
Analize PFS po podskupinah glede na pregled IRC na podlagi izhodiščnih značilnosti so bile skladne z rezultati primarne analize PFS.
Key secondary endpoints included objective response rate (ORR), duration of response (DoR), and overall survival (OS).
Ključni sekundarni opazovani dogodki so vključevali objektivni odziv na zdravljenje (ORR - Objective Response Rate), trajanje odziva (DoR - Duration of Response) in celokupno preživetje (OS - Overall Survival).
• Dry, red, or itchy eyes
• suhe, rdeče ali srbeče oči
If a test has shown that your cancer has certain changes (mutations) in a gene called ‘EGFR' (epidermal growth factor receptor) and has spread to your other lung or other organs, your cancer is likely to respond to treatment with Vizimpro.
Če preiskava pri vašem raku pokaže določene spremembe (mutacije) v genu, ki ga imenujemo ''EGFR'' (receptor za epidermalni rastni dejavnik), in se je vaš rak razširil na drugo pljučno krilo ali na druge organe, je verjetno, da se bo vaš rak odzval na zdravljenje z zdravilom Vizimpro.
The plasma half-life of dacomitinib ranges from 54 to 80 hours.
Plazemski razpolovni čas dakomitiniba je v razponu od 54 do 80 ur.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake ''EXP''.
This may mean that you have an inflammation of the lungs called interstitial lung disease and can be fatal.
To lahko pomeni, da imate vnetje pljuč, imenovano intersticijska pljučna bolezen, ki je lahko usodna.
If you feel tired or your eyes are irritated, you should use caution when driving or using machines.
Če ste utrujeni ali imate razdražene oči, morate biti pri upravljanju vozil ali strojev previdni.
Based on data from observations in 8 patients in Study A7471001, there was no apparent effect of local antacid administration on Cmax and AUCinf of dacomitinib.
Na podlagi podatkov iz opažanj pri 8 bolnikih v Študiji A7471001 ni bilo očitnega učinka dajanja lokalnega antacida na vrednosti Cmax in AUCinf dakomitiniba.
Early treatment of skin rash is important.
Zgodnje zdravljenje izpuščaja na koži je pomembno;
Vizimpro can be used as your first treatment once your lung cancer has spread to your other lung or other organs.
Zdravilo Vizimpro lahko uporabljamo kot prvo zdravljenje, ko se je vaš rak pljuč že razširil na drugo pljučno krilo ali na druge organe.
If you take more Vizimpro than you should If you have taken too much Vizimpro, see a doctor or go to a hospital immediately.
Če ste vzeli večji odmerek zdravila Vizimpro, kot bi smeli Če ste vzeli preveč zdravila Vizimpro, takoj obiščite zdravnika ali pojdite v bolnišnico.
The recommended dose of Vizimpro is 45 mg taken orally once daily, until disease progression or unacceptable toxicity occurs.
Priporočeni odmerek zdravila Vizimpro je 45 mg peroralno enkrat na dan do napredovanja bolezni ali nesprejemljive toksičnosti.
Treatment in this population is not recommended (see section 5.2).
Zdravljenje pri tej populaciji ni priporočljivo (glejte poglavje 5.2).
Effect of Dacomitinib on UGT Enzymes
Učinek dakomitiniba na encime UGT
What Vizimpro is and what it is used for 2.
Kaj je zdravilo Vizimpro in za kaj ga uporabljamo 2.
Dacomitinib binds selectively and irreversibly to its HER family targets thereby providing prolonged inhibition.
Dakomitinib se selektivno in ireverzibilno veže na svoja prijemališča družine HER in tako zagotavlja dolgotrajno zaviranje.
The primary endpoint of the study was progression-free survival (PFS) as determined by blinded Independent Radiology Central (IRC) review.
Primarni opazovani dogodek študije je bilo preživetje brez napredovanja bolezni (PFS - ProgressionFree Survival), kot so ga določili s slepim neodvisnim centralnim radiološkim (IRC - Independent Radiology Central) pregledom.
These effects were reversible with the exception of hair follicles and kidney changes.
Ti učinki so bili reverzibilni, z izjemo sprememb lasnih mešičkov in ledvic.
Skin-related adverse reactions were Grades 1 to 3.
S kožo povezani neželeni učinki so bili stopnje 1-3.
If treatment for rash is not working or the rash is getting worse (for example, you have peeling or cracking of the skin) you should tell your doctor immediately, since your doctor may decide to stop your treatment with Vizimpro.
Če zdravljenje izpuščaja ni učinkovito ali se izpuščaj poslabšuje (na primer se vam koža lušči ali poka), takoj obvestite zdravnika, saj se zdravnik lahko odloči za prekinitev vašega zdravljenja z zdravilom Vizimpro.
Recommended starting dose
priporočeni začetni odmerek
• Pimozide and thioridazine, used to treat schizophrenia and psychosis
• pimozid in tioridazin, ki se uporabljata za zdravljenje shizofrenije in psihoze.
Treatment with Vizimpro should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
Zdravljenje z zdravilom Vizimpro mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje rakavih bolezni.